SMS Pharmaceuticals Ltd
NSE:SMSPHARMA
SMS Pharmaceuticals Ltd
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing active pharma ingredients (API) and their intermediates. The firm's API products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Pantoprazole Sodium Sesquihydrate US/Ph. Eur, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP, Sumatriptan Succinate USP / Ph.Eur/ BP, Sumatriptan Base USP / Ph.Eur/ BP, Almotriptan Malate, Zolmitriptan, Rizatriptan Benzoate USP/ Ph.Eur, Eletriptan Hydrobromide Monohydrate, Sildenafil Citrate USP / Ph.Eur, Tadalafil USP / Ph.Eur, Vardenafil and others. The firm's manufacturing facilities are located in Bachupally, Hyderabad in the state of Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram district in Andhra Pradesh. Its research and development (R&D) center is located in Gagillapur, Hyderabad.
SMS Pharmaceuticals Ltd. is a holding company, which engages in the research, development and marketing of active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2007-02-25. The firm is engaged in the business of manufacturing active pharma ingredients (API) and their intermediates. The firm's API products include Ranitidine HCL (Form-2) USP / Ph.Eur, Famotidine USP / Ph. Eur / JP, Pantoprazole Sodium Sesquihydrate US/Ph. Eur, Itraconazole USP / Ph.Eur / JP, Lanoconazole USP / JP, Sumatriptan Succinate USP / Ph.Eur/ BP, Sumatriptan Base USP / Ph.Eur/ BP, Almotriptan Malate, Zolmitriptan, Rizatriptan Benzoate USP/ Ph.Eur, Eletriptan Hydrobromide Monohydrate, Sildenafil Citrate USP / Ph.Eur, Tadalafil USP / Ph.Eur, Vardenafil and others. The firm's manufacturing facilities are located in Bachupally, Hyderabad in the state of Telangana and also at Kandivalasa Village, Poosapatirega Mandal, Vijayanagaram district in Andhra Pradesh. Its research and development (R&D) center is located in Gagillapur, Hyderabad.
PAT Growth: Profit after tax surged 80% year-on-year to INR 25.3 crores, marking the highest quarterly PAT for the company.
Revenue Expansion: Q2 revenue grew 23% YoY to INR 242.4 crores, with H1 revenue reaching INR 438.4 crores (up 21% YoY), driven by strong API demand and market share gains.
Margin Improvement: Gross margin rose to 32% and EBITDA margin expanded to 20%, supported by backward integration and product mix optimization.
Backward Integration Impact: Management highlighted backward integration as a key driver for cost competitiveness, margin gains, and reduced reliance on Chinese suppliers.
CapEx and R&D Investment: The INR 280 crore CapEx program remains on track for completion by November 2026, with new R&D and greenfield initiatives lined up for future growth.
Product & Customer Diversification: No single therapeutic category contributed more than 24% to revenue, underlining a diversified portfolio.
Positive Outlook: Management reiterated confidence in achieving around 20% revenue growth and 20% EBITDA margin for FY '26.
